金斯瑞(01548.HK)斥2.25亿美元增持CDMO服务附属Probio Cayman

阿斯达克财经
28 Apr

金斯瑞生物科技(01548.HK) 公布关连交易,向MUSM VII及HSUM XIV收购Probio Cayman合共3亿股A类优先股,总代价2.25亿美元(约17亿港元)。完成后,公司持有Probio Cayman权益将由目前71.72%增至85.09%,后者主要为生物科技及制药公司提供全面的合约开发及生产组织(CDMO)服务。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-28 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10